Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study

NCT05180851 is registered in ClinicalTrials.gov with Shanghai Fengxian District Central Hospital as lead sponsor.

NCT NCT05180851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05180851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study
Lead sponsor
Shanghai Fengxian District Central Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2021
Completion date
December 31, 2023
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, cervical carcinoma, head and neck cancer, lung cancer, melanoma, ovarian carcinoma